Study: Psoriasis drug boosts insulin secretion in type 1 diabetes

09/23/2013 |

Type 1 diabetes patients who received the psoriasis medication alefacept attained significant improvements in preserved insulin secretion at four hours compared with those in the placebo group, according to a study in The Lancet Diabetes & Endocrinology. Researchers also found patients in the alefacept arm were using less supplementary insulin and were less likely than those in the control group to experience hypoglycemic episodes one year after starting treatment.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ